Skip to Content

Fluphenazine Pregnancy and Breastfeeding Warnings

Fluphenazine is also known as: Permitil, Prolixin, Prolixin Decanoate, Prolixin Enanthate

Fluphenazine Pregnancy Warnings

Animal models have revealed evidence of dilated cerebral ventricles, skeletal defects, and reductions in fetal weight and length. Abnormal sperm and chromosomal aberrations have occurred in male animals receiving antipsychotic agents, and depression of spermatogenesis occurred at high doses. There are no controlled data in human pregnancy. AU TGA pregnancy category C: Drugs which, owing to their pharmacological effects, have caused or may be suspected of causing, harmful effects on the human fetus or neonate without causing malformations. These effects may be reversible. Accompanying texts should be consulted for further details. US FDA pregnancy category Not Assigned: The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help health care providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D, and X are being phased out.

This drug should be used during pregnancy only if the benefit outweighs the risk to the fetus. AU TGA pregnancy category: C US FDA pregnancy category: Not formally assigned. Risk Summary: Neonates exposed during the third trimester are at risk of developing severe and/or prolonged side effects (e.g., agitation, hyper/hypotonia, tremor, somnolence, respiratory distress, feeding disorder). The side effects have varied in severity and duration, with some neonates requiring intensive care support and prolonged hospitalization. Comments: -The dose and duration of treatment in pregnant patients should be as low and short as possible. -Exposed neonates should be monitored for the signs/symptoms of extrapyramidal syndrome and/or withdrawal.

See references

Fluphenazine Breastfeeding Warnings

Use is not recommended. Excreted into human milk: Unknown Excreted into animal milk: Unknown Comments: -The American Academy of Pediatrics considers use of this drug during lactation "unknown but may be of concern." -Breastfed infants exposed to this drug should be monitored for sedation and developmental milestones.

This drug may cause hyperprolactinemia and galactorrhea, which could impair lactation.

See references

References for pregnancy information

  1. "Product Information. Prolixin (fluphenazine)." Apothecon Inc, Plainsboro, NJ.
  2. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  3. Cleary MF "Fluphenazine decanoate during pregnancy." Am J Psychiatry 134 (1977): 815-6
  4. Cerner Multum, Inc. "Australian Product Information." O 0

References for breastfeeding information

  1. "Product Information. Prolixin (fluphenazine)." Apothecon Inc, Plainsboro, NJ.
  2. Cerner Multum, Inc. "Australian Product Information." O 0
  3. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  4. "Product Information. Prolixin (fluphenazine)." Bristol-Myers Squibb, Princeton, NJ.
  5. United States National Library of Medicine "Toxnet. Toxicology Data Network. Available from: URL: http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT." ([cited 2013 -]):

See Also...

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and Drugs.com is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide